Pharmascience in Brief

Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Québec with over 1,500 employees proudly headquartered in Montréal. Pharmascience Inc. is a full-service, privately owned pharmaceutical company that has strong roots in Canada and a growing global reach, with product distribution in over 60 countries. Ranked 56th among Canada's top 100 Research & Development (R&D) investors with over $43 million invested in 2017, Pharmascience Inc. is the third-largest manufacturer of over-the-counter generic drugs in the country.

Pharmascience Inc. is a leading manufacturer and marketer of prescription generic, over-the-counter, and behind-the-counter products as well as FDA-approved Canadian-made injectables. The company commercializes nearly 300 product families in 20 different dosage forms for over 2,000 products. In Canada alone, more than 45 million prescriptions a year are filled with Pharmascience products.

In 2018, Forbes magazine ranked Pharmascience Inc. among its list of top 300 employers. Pharmascience Inc. has strong long-standing philanthropic ties with its communities, both locally and internationally. For more than 20 years, Pharmascience has been working through Health Partners International of Canada (HPIC) as a partner of choice to increase access to medicine. Pharmascience's donations of essential medicine total close to $70 million. 

 

Pharmascience Quick Facts

  •   1.
    Co-founded by pharmacists Morris Goodman and Ted Wise in 1983;
  •   2.
    Largest pharmaceutical employer in Quebec with 1,500 employees;
  •   3.
    Third largest generic pharmaceutical company in Canada;
  •   4.
    Ranked 51st among Canada's top 100 R&D investors with CAD $49 million invested annually;
  •   5.
    Diversified portfolio of over 300 product families, both prescription and OTC;
  •   6.
    Sales in more than 60 countries;
  •   7.
    One of the largest providers of generic single-source products;
  •   8.
    A leader in customer service & support.

Morris Goodman

Chairman of the Board

As one of Canada's leading entrepreneurs and a pioneer in the generic drug industry, Mr. Goodman has dedicated his career to "Creating the Difference" in healthcare in Canada and worldwide. He graduated from the Faculty of Pharmacy at the University of Montreal in 1953 at the young age of twenty-one.

After graduation, Mr. Goodman focused on the industry side of pharmacy and quickly obtained distribution rights from several international pharmaceutical companies to bring their products to the Canadian marketplace. He marketed and sold these products in Canada under the company name of Winley-Morris Co. Ltd.

In 1971, Mr. Goodman approached a California-based company, International Chemical & Nuclear Corporation (ICN) and became their Canadian distributor of L-Dopa. Impressed with his innovative approach, they purchased Winley-Morris and established Morris Goodman as President of ICN Canada.

In 1983, Mr. Goodman co-founded Pharmascience Inc. with his good friend and colleague, Ted Wise. As Co-Founder & Chairman of the Board of Pharmascience Inc., Morris Goodman has been at the forefront of the company's explosive growth and development, leading it to its current standing as one of the top three generic pharmaceutical companies in Canada.

Notwithstanding his business successes, Mr. Goodman is a leader in philanthropic initiatives. Included among the major charitable donations made by The Morris & Rosalind Goodman Family Foundation are The Stroke Unit at the Jewish General Hospital, the Agora at the Faculty of Pharmacy at the University of Montreal and The Goodman Cancer Research Centre at McGill University.

In May of 2011, McGill University bestowed an honorary degree upon Mr. Goodman.

David Goodman

Chief Executive Officer

Dr. David Goodman is Chief Executive Officer of Pharmascience, which is today the 2nd largest privately-owned pharmaceutical company in Canada.

Dr. Goodman obtained his Bachelor degree in Commerce from McGill University, and his Ph.D. in pharmacology from the University of Virginia. Upon graduation, he began his career at Pharmascience in Business Development and has gained significant experience in progressively senior international and domestic roles.

Under Dr. Goodman's leadership, Pharmascience has gone from being a strictly Canadian company to becoming an important player on the global stage. Pharmascience strives to be the first company to launch its generic pipeline in Canada, Europe and various markets throughout the world.

Dr. Goodman's success is his belief and insistence on major and constant investment in internal and external R&D programs, as well as in employee development.

Jean-Guy Goulet

Chief Operating Officer

Since his arrival at Pharmascience in May 2017 as Chief Operating Officer, Jean-Guy Goulet has led the generic medicines commercialization activities both in Canada and abroad as well as all activities related to production, quality and supply chain management.

His unique combination of life experiences has inspired his management approach. A graduate in chemistry from the University of Montreal, he understands the importance of demonstrating rigor in all circumstances. Once a pitcher, who had considered a professional career in baseball, he knows how to surround himself with talented players in different positions to build a series of winning teams. A self-taught manager, his intuition and versatility lead him to develop a participatory management approach that inspires his colleagues to apply their sense of passion, initiative and accountability to their work.

His professional career began in 1987 at Technilab Pharma's Quality Control Department, a company later acquired by the German society ratiopharm. He successively held various positions of increasing responsibility in various departments such as Operations, Sales, Marketing and Business Development. From 2002 to 2006, he was President of ratiopharm’s Canadian Commercial Division. After which, he led the North American Commercial Division as President between 2006 and 2010. In 2011, he joined Watson plc, which became Actavis in 2012. He then headed Actavis for both Canada and Latin America, until they acquired Allergan in April 2015. Shortly after, he became President of Actavis Canada, until its acquisition by a world leader in the pharmaceutical industry in 2016.

An influential member of the Canadian Generic Pharmaceutical Association (CGPA), he chaired the Board of Directors from 2002 to 2006.  He was also involved in various negotiations during the review of federal patent laws between 1993-2006 as well as being on the negotiating committee of the Pan-Canadian Pharmaceutical Alliance.

An avid golfer, maple syrup producer and oenophile, Jean-Guy never misses an opportunity to share with his family and friends the joy which accompanies his various passions.